Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitor”

2,878 pharma patents match "inhibitor" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,878
Index total 30,257
Page 22 / 120

Quick answer

This filtered view shows 2,878 pharmaceutical patents matching "inhibitor" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,878 results for “inhibitor” · 30,257 patents in full index Clear search

  1. US 11427581

    JAK inhibitor and use thereof

    ZHUHAI UNITED LABORATORIES CO., LTD. · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted
  2. US 11420965

    Pyrimidine compound as JAK kinase inhibitor

    Theravance Biopharma R&D IP, LLC · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted
  3. US 11420936

    Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases

    NIKANG THERAPEUTICS, INC. · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted
  4. US 11414379

    SPAK kinase inhibitors as neuroprotective agents

    United States Government as represented by the Department of Veterans Affairs · Granted Aug 16, 2022 · Expires Aug 11, 2042

    granted
  5. US 11414489

    Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor

    HALOZYME, INC. · Granted Aug 16, 2022 · Expires Aug 11, 2042

    granted
  6. US 11407998

    Twist signaling inhibitor compositions and methods of using the same

    The Regents of the University of California · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted
  7. US 11406713

    Xanthine oxidase inhibitor formulations

    XORTX THERAPEUTICS, INC. · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted
  8. US 11407723

    Selective histone deacetylase inhibitors for the treatment of human disease

    Shuttle Pharmaceuticals, Inc. · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted
  9. US 11407712

    Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α

    Arcus Biosciences, Inc. · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted
  10. US 11407736

    RIP1 inhibitory compounds and methods for making and using the same

    Rigel Pharmaceuticals, Inc. · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted
  11. US 11401286

    Heteroaryl inhibitors of PDE4

    Tetra Discovery Partners · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted
  12. US 11401246

    Triazole glycolate oxidase inhibitors

    Century Therapeutics, Inc. · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted
  13. US 11390631

    Benzodiazepine derivatives as RSV inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  14. US 11389433

    BRD4 inhibitor treatment of IgE-mediated diseases

    The Board of Regents of the University of Texas System · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  15. US 11390646

    Structure-based peptide inhibitors of α-synuclein aggregation

    The Regents of the University of California · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  16. US 11384065

    Heterocyclic compound as CSF-1R inhibitor and use thereof

    Medshine Discovery Inc. · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  17. US 11382955

    Long-acting VEGF inhibitors for intraocular neovascularization

    The Regents of the University of California · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  18. US 11384076

    Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors

    Universität Regensburg · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  19. US 11384055

    Glycolate oxidase inhibitors for the treatment of disease

    BIOMARIN PHARMACEUTICAL INC. · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  20. US 11377428

    RIP1 inhibitory compounds and methods for making and using the same

    Rigel Pharmaceuticals, Inc. · Granted Jul 5, 2022 · Expires Jun 30, 2042

    granted
  21. US 11377444

    Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors

    Medshine Discovery Inc. · Granted Jul 5, 2022 · Expires Jun 30, 2042

    granted
  22. US 11376247

    Tyrosine kinase inhibitors regenerate non-cancerous tissue after cancer therapy

    The Regents of the University of Colorado, a Body Corporate · Granted Jul 5, 2022 · Expires Jun 30, 2042

    granted
  23. US 11377469

    CD73 inhibitors

    ORIC PHARMACEUTICALS, INC. · Granted Jul 5, 2022 · Expires Jun 30, 2042

    granted
  24. US 11370774

    Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Jun 28, 2022 · Expires Jun 23, 2042

    granted